Amin Khan

 

M. Amin Khan, PhD, with 30+ years in pharmaceutical and vaccine R&D across large Pharma and small Biotech, has played critical roles in integrated R&D programs demonstrating rapid clinical translation, and navigating the late-stage development of vaccine products. Currently, he is an advisor to vaccine and biologics companies operating in the Americas, Europe and Africa, and serves on Scientific Advisory Boards, and Corporate Governance Boards for numerous companies.

 

Most recently he was the Executive Vice President and Head of R&D at Icosavax, Inc., (acquired by AstraZeneca, February 2024). Amin has held senior scientific and executive leadership roles at Eli Lilly, Novartis Vaccines and GlaxoSmithKline. He has guided scientific and technical teams to develop novel vaccines for infectious diseases including targets for RSV, influenza, meningitis, group B streptococcus, S. aureus, COPD, CMV, herpes zoster and SARS-Cov-2, and has contributed to the licensure of four vaccines. These programs utilized a broad range of enabling technologies including recombinant proteins, viral vectors and nucleic acids. Amin holds a PhD in Pharmaceutical Sciences from the University of Nottingham, UK.